Genelux (GNLX) to Release Quarterly Earnings on Thursday

Genelux (NASDAQ:GNLX - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Genelux (NASDAQ:GNLX - Get Free Report) last released its earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Price Performance

Shares of NASDAQ:GNLX traded down $0.10 during mid-day trading on Tuesday, reaching $2.41. 7,664 shares of the company traded hands, compared to its average volume of 208,542. Genelux has a 52 week low of $1.60 and a 52 week high of $5.89. The firm has a market cap of $90.94 million, a PE ratio of -2.53 and a beta of -0.33. The company's 50 day moving average price is $3.07 and its 200-day moving average price is $3.12.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Genelux in a research report on Monday, March 31st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $18.25.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.